United States healthcare spending surged by an alarming 7.3% last year, reaching an unprecedented $5.7 trillion, a dramatic increase driven primarily by escalating utilization of hospital services and the rapid adoption of expensive prescription medications, most notably GLP-1 receptor agonists. This significant jump in expenditure, detailed in new government data released by the Centers for Medicare & Medicaid Services (CMS), highlights a persistent and intensifying financial burden on the nation’s economy and its citizens. The revelation underscores a critical moment for policymakers, healthcare providers, and the public, as the country grapples with a healthcare system whose costs continue to outpace overall economic growth.
Drivers of Escalation: Consumption Over Price
Contrary to common assumptions, the primary catalyst for this sharp spending growth is not a sudden spike in prices for individual services, which have seen moderate increases. Instead, CMS actuaries point to a substantial increase in healthcare consumption by Americans. This trend signifies a significant rebound in healthcare seeking behaviors following a period of deferred care during the initial phases of the coronavirus pandemic. Many individuals are now catching up on preventative screenings, elective procedures, and managing chronic conditions that may have worsened due to delayed intervention. This pattern echoes observations from the 2024 national health expenditures report, indicating a sustained upward trajectory in demand for medical services.
Jacqueline Fiore, an economist with CMS’s Office of the Actuary, expressed surprise at the magnitude of last year’s growth. "Spending growth continued to grow more rapidly for 2025 than we had expected," Fiore stated during a press call discussing the projections, which were concurrently published in the esteemed journal Health Affairs. This unexpected acceleration points to underlying systemic pressures that are proving more potent than previous forecasts had anticipated.
The GLP-1 Phenomenon: A Game-Changer with a High Price Tag
Among the most significant forces accelerating current and projected spending is the soaring demand for retail prescription drugs. This category is forecast to experience the fastest growth over the next decade, with particular intensity expected in 2025 and 2026. This surge is largely attributable to increased utilization of costly medications for conditions such as cancer, but the undisputed powerhouse driving this trend is the "rabid demand" for GLP-1s.
GLP-1 receptor agonists, initially developed for the treatment of Type 2 diabetes, have seen their application rapidly expand to include other conditions, most notably chronic weight management. Public interest and medical prescriptions for these drugs have skyrocketed, with a recent KFF poll indicating that one in eight American adults report currently taking a GLP-1 drug for weight loss, diabetes, or another condition. While offering transformative health benefits for many, these medications come with a substantial financial cost, often exceeding $1,000 per month out-of-pocket without adequate insurance coverage.
John Poisal, the deputy director of the National Health Statistics Group in CMS’s Office of the Actuary, explicitly identified GLP-1s as a "big, big part" of the current spike in U.S. health spending. He elaborated, "that is pushing growth rates up for private health insurance for sure, for Medicare for sure." The widespread adoption of these drugs across various payer types, coupled with their high unit cost, creates a potent combination for expenditure growth that health systems and insurers are struggling to absorb. The manufacturers, primarily Novo Nordisk (with Ozempic and Wegovy) and Eli Lilly (with Mounjaro and Zepbound), have seen their market capitalizations soar, highlighting the immense commercial success of these pharmaceutical innovations, even as they contribute significantly to national spending challenges.
Economic Implications: A Growing Slice of the GDP
The findings from CMS paint a stark picture of healthcare’s growing burden on the national economy. For the third consecutive year, U.S. health spending increased faster than 7%, consistently outpacing the overall economic growth rate. This widening mismatch is projected to persist over the coming years, leading the healthcare sector to consume progressively larger shares of the U.S. gross domestic product (GDP).
National health spending, which stood at 18% of the GDP in 2024, is now projected to swell to an astonishing 20.6% by 2034, at which point it is expected to account for a whopping $9 trillion in annual spending. This trajectory represents an alarming increase in the proportion of the nation’s economic output dedicated to healthcare, with profound implications for other sectors, public services, and individual economic well-being. Historically, the U.S. has consistently allocated a larger share of its GDP to healthcare than any other developed nation, yet often achieves poorer health outcomes, a paradox that intensifies calls for systemic reform.
The Fiscal Strain on Federal and State Coffers
The projected growth places immense fiscal strain on government budgets. Medicare, the federal health insurance program for seniors and certain disabled individuals, is set to experience the fastest growth rate among all payer types. Its share of national health spending is expected to rise from 31% in 2024 to 33% by 2034, translating to an annual growth rate of 7.7% through the decade. This increase is driven by the aging of the vast Baby Boomer generation, with the youngest cohorts now entering the program and older beneficiaries requiring more intensive and costly care.
Medicaid, the joint federal and state program for low-income individuals, also faces significant, albeit moderating, growth at 5% annually. While its growth is expected to slow this year due to recent policy changes, the sheer scale of its enrollment and the increasing complexity of care for its beneficiaries mean it remains a substantial line item for both federal and state budgets. State and local governments are projected to maintain their share of national spending at 16%, but this stability belies the increasing dollar amounts they will need to contribute.
Impact on Employers and Households
The private sector is not immune to these rising costs. Private health insurance spending is projected to grow at an annual rate of 5%. While per-enrollee spending is set to jump due to a higher acuity population remaining in the exchanges after policy changes, the overall share of national spending borne by U.S. employers is expected to shrink slightly, from 18% in 2024 to 17% by 2034. This reduction, however, does not necessarily translate to relief for businesses. Instead, it often manifests as stagnant wage growth, higher employee contributions, or a reduction in benefits as companies attempt to manage their own rising healthcare expenditures. Households, through out-of-pocket spending, are projected to see a 4.7% annual growth, maintaining their 28% share of national spending, reflecting the increasing direct financial burden on individuals.
Policy Landscape and Future Outlook
The trajectory of healthcare spending is inextricably linked to policy decisions emanating from Washington. Overall health spending growth is anticipated to remain especially high through the end of this year, after which CMS expects a moderation as a result of recent legislative changes. These include controversial Medicaid cuts embedded in the Republican-led Congress’s "Big Beautiful Bill" and the expiration of more generous subsidies for Affordable Care Act (ACA) plans.
Shifting Insurance Landscape: ACA Subsidies and Medicaid Cuts
The legislative provisions enacted during the Trump administration and continued through recent budget cycles are set to reshape the U.S. insurance landscape and national health spending over the coming decade. In 2024, 91.8% of the U.S. population was insured. However, this figure is projected to decline to 90.8% this year, dipping further to 90.5% by 2034. This reduction in the insured population is primarily attributed to two significant policy shifts.
Firstly, the expiration of enhanced subsidies for ACA plans, which had made coverage more affordable for millions, has priced many Americans out of the exchanges established by the Obama-era law. This battle saw Democrats advocating for an extension and Republicans lobbying against it, ultimately resulting in the subsidies lapsing at the end of 2025. This has led to a smaller, and importantly, higher acuity population remaining in the exchanges, driving up per-enrollee spending for those who retain coverage. Insurers have consistently reported being left with a sicker pool of enrollees, necessitating higher spending per individual.
Secondly, the Medicaid cuts enacted through the "Big Beautiful Bill," a budget reconciliation legislation passed last summer, aim to curb funding and enrollment in the safety-net program. These provisions include restrictions on mechanisms states use to boost their federal Medicaid funding and, critically, a requirement that certain enrollees meet monthly work requirements to continue receiving Medicaid coverage. "Together, these legislative provisions play a role in reducing the insured share of the population," Fiore confirmed, underscoring the direct link between policy and access to care.
Medicaid Growth Slows Amidst Policy Revisions
As a direct consequence of these provisions, Medicaid spending growth is expected to decelerate this year. While potentially easing the immediate financial burden on federal and state budgets, these measures also carry the implication of increasing the number of uninsured Americans over the next decade. Patient advocates and public health experts have voiced concerns that these cuts could lead to a deterioration of health outcomes for vulnerable populations, as access to essential medical services becomes more challenging.
Medicare’s Looming Fiscal Challenge
The most significant fiscal challenge, however, lies with Medicare. As the youngest wave of Baby Boomers ages into the program and the oldest cohorts require increasingly comprehensive and costly care, Medicare spending is projected to grow at an annual rate of 7.7% through 2034. This rate is substantially higher than the growth projected for Medicaid (5%), private health insurance (5%), or out-of-pocket spending (4.7%). The program’s Hospital Insurance (HI) Trust Fund, which pays for inpatient hospital stays and other services, faces an ongoing solvency challenge, with projections indicating its inability to cover full benefits within the next decade if no legislative action is taken. This demographic reality, combined with rising per capita costs, ensures that Medicare will remain a central point of debate for future fiscal policy.
Private Health Insurance Navigates Rising Acuity
Private health insurance, while seeing overall spending growth moderate slightly, is experiencing its own set of challenges. As mentioned, the loss of ACA subsidies has led to a smaller and higher acuity population remaining in the exchanges. This means that while fewer people may be covered by private plans obtained through the exchanges, those who are insured are often sicker and require more extensive, and therefore more expensive, care. This dynamic forces insurers to adjust premiums, plan designs, and provider networks, often leading to higher costs for employers and individuals who remain in the market.
The Broader Debate: Value, Access, and International Comparisons
The new CMS projections are not merely statistical data; they are a stark reminder of healthcare’s enduring and escalating burden on the nation’s coffers. The United States notoriously spends more on healthcare than any other wealthy nation—nearly twice as much per capita—yet consistently lags behind its peers in crucial health outcomes. Metrics such as life expectancy, preventable deaths, and maternal mortality often place the U.S. at or near the bottom among comparable countries. This stark disparity fuels the long-standing debate among patient advocates, value-based care evangelists, and budget hawks: is the U.S. truly getting "bang for its buck" from its massive healthcare investment?
Critics of the current system argue that the profit motivations inherent in a largely private healthcare market, particularly among pharmaceutical companies and some insurers, incentivize maintaining the status quo rather than pursuing aggressive cost-containment strategies or prioritizing population health over revenue. Voluntary commitments from private healthcare companies to lower costs, a strategy sometimes favored by administrations, are often slammed as ineffective given these inherent profit drivers.
Policymakers Grapple with a Defining Challenge
The release of these new projections is expected to intensify attention on healthcare costs, especially as lawmakers gear up for November’s midterm elections, where healthcare affordability and access are perennial top issues. The political landscape is fractured, with differing approaches to reform. Some advocate for market-based solutions and deregulation, believing competition will drive down costs. Others champion greater government intervention, whether through price controls, expanded public insurance options, or more robust regulation of the pharmaceutical and insurance industries.
"Policymakers will undoubtedly continue to explore options for addressing the significant financing challenges for a sector that is expected to account for more than one-fifth of the economy by 2034," CMS actuaries concluded in their report. This statement encapsulates the immense task ahead. The rising tide of healthcare spending is not just an economic concern; it is a fundamental challenge to the nation’s fiscal stability, public health, and individual well-being, demanding urgent and comprehensive attention from all stakeholders. The path forward remains contentious, but the imperative to address the accelerating costs and persistent inequities of the U.S. healthcare system has never been clearer.
